Background-Patients with peripheral artery disease (PAD) are at high risk of cardiovascular events and benefit from aggressive secondary prevention; however, changes in the use of cardioprotective medications after incident diagnosis of PAD have not been well described. Methods and Results-We used Danish nationwide administrative registries (2000 -2007) to identify 2 groups with incident PAD: PAD alone (nϭ34 160) and PAD with history of coronary artery disease (CAD) (nϭ9570). With the use of a comparator with incident CAD alone (nϭ154 183), we assessed temporal trends and comparative use of cardioprotective medications. Relative differences in medication use were examined by using multivariable logistic regression. Use of medications improved temporally among both groups: for PAD alone, any antiplatelet use increased from 29% to 59% from 2000 to 2007 (PϽ0.0001), whereas statin use increased 6-fold (9%-56%; PϽ0.0001). However, use of these therapies by 18 months after incident diagnosis for both PAD groups remained modest and lower in comparison with CAD alone (any antiplatelet, 53% versus 66%; statins, 40% versus 52%; angiotensin-converting enzyme inhibitors, 20% versus 29%). Relative to CAD alone, patients with PAD alone were less likely to use any antiplatelet (adjusted odds ratio, 0.50; 95% confidence interval, 0. 
describing the use of cardioprotective agents in patients with PAD. Previous analyses of PAD cohorts have been limited in that they traditionally relied on questionnaires to determine the use of medications, lacked complete data on medication use, such as aspirin, did not capture longitudinal follow-up, and could not determine the timing of incident diagnosis. Danish administrative registries are unique in that they capture medication adherence by tracking all filled prescriptions in the national health care system. With the use of this dataset and patients with incident diagnosis of CAD as the comparators, we sought to (1) investigate the use of cardioprotective therapies within 18 months of incident diagnosis of PAD and (2) describe the change in the use of these medications over time.
Methods

Study Design and Data Sources
We conducted a population-based cohort study in Denmark using nationwide administrative registries from January 2000 through June 2009. All Danish residents have a unique, permanent personal identification number that enables individual-level linkage of administrative registries.
Information on diagnoses and comorbidity was obtained from the Danish National Hospital Registry, which holds data on all admissions and outpatient visits to Danish hospitals and specialty clinics since 1978. 22 Since 1994, each admission/visit is registered by a primary diagnosis and, if appropriate, secondary diagnoses according to the International Classification of Diseases, 10th Revision (ICD-10).
Data on prescription drug use were obtained from the national prescription register (the Danish Register of Medicinal Product Statistics). All filled prescriptions in Denmark have been recorded in this registry since 1995; this provides complete data on date of dispensing, strength of tablets, and number of pills dispensed. Medications are classified according to the international Anatomic Therapeutic Chemical (ATC) system. Because drug expenses are partially reimbursed by the health care system, pharmacies in Denmark must register dispensed prescriptions in the national prescription register. This ensures a highly accurate registry. 23 
Covariates
Comorbidity was measured by the use of the Charlson comorbidity index by assessing hospitalizations 1 year before diagnosis, as described by Charlson et al 24 and Deyo et al. 25 The Charlson comorbidity index includes important covariates, such as previous stroke and history of atrial fibrillation, and was used in the present study for characterization of patients and standardized model adjustment. Patients were categorized as diabetic if they had a recorded diagnosis or filled at least 1 prescription for a glucose-lowering drug within 6 months of the incident diagnosis of PAD or CAD. Prescriptions filled 3 months before the incident date of diagnosis were examined to assess concomitant pharmacotherapy (baseline medications). Rates of myocardial infarction (hospitalization with ICD-10 codes I21.x-I22.x as primary or secondary codes), percutaneous coronary intervention (Danish Board of Health classification code KFNG), and lower-extremity revascularization (online-only Data Supplement Table I ) within 18 months after incident diagnosis of PAD or CAD were also assessed, because these may have influenced the use of cardioprotective medications.
Study Population
In brief, the study population was identified among all Danish residents Ն40 years of age at time of diagnosis and after January 1, 2000. Patients with incident diagnosis of PAD were classified into 2 groups: (1) the PAD alone group-those with incident diagnosis of lower-extremity PAD with no history of CAD (first-time hospitalization or at least 2 consecutive outpatient visits for PAD) (onlineonly Data Supplement Table IIA) and (2) the PAD with history of  CAD group-patients with history of CAD (online-only Data Supplement Table IIB ) and then incident diagnosis of PAD. For brevity, this group is referred to as the PAD with CAD group. A third group of patients, the CAD alone group, was identified to compare use rates and temporal changes in the use of cardioprotective medications with the 2 PAD groups; the CAD alone group comprised patients with incident diagnosis of CAD (1 hospitalization or at least 2 consecutive outpatient visits) who had no history of PAD. We used patients with CAD as the comparator, because patients with CAD alone have recommendations for the use of similar cardioprotective medications. 26, 27 The index date used for the analysis was the time of incident diagnosis of PAD for the first 2 groups and the time of incident diagnosis of CAD for the third group. Patients taking vitamin K antagonists (ATC code B01AA) before and after the index date of diagnosis were excluded, because these medications strongly influence the rates of antiplatelet therapy in all 3 groups (Figure 1 ).
Exposure: Cardioprotective Medications
Use of all cardioprotective medications was assessed 3 months before diagnosis, to determine baseline use, and in 3-month intervals after diagnosis up to 18 months. Patients were categorized as users if they filled at least 1 prescription for the individual drug during a 3-month period, as done previously. 28, 29 The cardioprotective medications were identified by the following: (a) aspirin monotherapy (ATC codes B01AC06 or N02BA01); (b) clopidogrel monotherapy (ATC code B01AC04); (c) statins (ATC code C10AA); and (d) ACE inhibitors (ATC code C09A). The American College of Cardiology/ American Heart Association PAD guidelines have provided class I indications for antiplatelet therapy (either aspirin or clopidogrel) and statin therapy for treatment of patients with coronary and peripheral vascular disease, 26, 27 and a class IIa recommendation for ACE inhibitors for treatment of vascular disease. Antiplatelet therapy and statins have both been incorporated into performance measures. 13 Dual antiplatelet therapy was defined as concomitant aspirin and clopidogrel therapy within the same 3-month period, and this was exclusive. Hence, patients on dual antiplatelet therapy were not counted in the aspirin and the clopidogrel monotherapy groups. Any antiplatelet therapy was defined as the use of aspirin monotherapy, clopidogrel monotherapy, or dual antiplatelet therapy.
Outcomes
The primary outcomes of interest were the use of cardioprotective medications within 18 months (in 3-month intervals) of incident diagnosis of PAD or CAD and annual change over time in the use of cardioprotective agents (within the first 3 months of incident diagnosis).
Statistical Analysis
We used the Kruskal-Wallis test for continuous variables and 2 tests for categorical variables to test for differences among groups. To quantify the use of cardioprotective medications as a function of time, we calculated the number of patients who claimed at least 1 prescription during the time interval of interest and who were alive and not concomitantly prescribed a vitamin K antagonist. Results are reported for any antiplatelet therapy, statin therapy, and ACE inhibitor. The online-only Data Supplement also includes results for aspirin monotherapy, clopidogrel monotherapy, and dual antiplatelet therapy. Temporal trends in the use of cardioprotective medications within 3 months of diagnosis were assessed by calculating proportions of patients being prescribed the drugs per calendar year. Frequencies in 2000 and 2007 were compared by the use of the Cochran-Armitage trend test. We performed multivariable logistic regression to assess relative differences in the use of cardioprotective medications. With the use of the CAD alone group as reference, the adjusted odds ratios (ORs) for use of medications in the 2 PAD groups were calculated and adjusted for age, sex, temporal trends, diabetes mellitus, subsequent myocardial infarction or percutaneous coronary intervention, lower-extremity revascularization, and the Charlson comorbidity index. The adjusted ORs for use of medications were calculated for the time immediately following incident diagnosis (within the first 3 months) and at 18 months after diagnosis. These 2 time points highlight the difference in the use of cardioprotective medications immediately after incident diagnosis, and later on, as well, when patients would be on a more stable, long-term regimen and the influence of acute hospitalization for CAD would be minimized. A sensitivity analysis was also performed for patients from 2005 to 2007, after which the PAD guideline recommendations were published (nϭ54 732). 5 In addition, a sensitivity analysis was performed to assess relative differences in the use of cardioprotective medication among symptomatic patients with specific ICD-10 codes for diagnosis of intermittent claudication (nϭ8794) and critical limb ischemia with atherosclerotic gangrene or rest pain (nϭ3459). Furthermore, results were also examined without excluding patients taking vitamin K antagonists. All analyses were performed using SAS, version 9.2 (SAS Institute Inc, NC) and the level of statistical significance was set at PՅ0.05.
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Results
Among all Danish residents aged Ն40 years from January 1, 2000 to December 31, 2007 (nϭ2 470 856), we identified 34 160 patients with incident PAD alone, 9570 patients with incident PAD with CAD, and 154 183 patients with incident CAD alone (Table) . Baseline characteristics and medication use before diagnosis according to group are described in the Table; patients in the PAD with CAD group had the highest frequency of comorbidities and highest use of cardioprotective medications overall at baseline, followed by the CAD alone group, and then the PAD alone group. In comparison with those in the PAD with CAD group, more patients in the PAD alone group were diagnosed with incident PAD in the outpatient setting (43% versus 54%, respectively). Patients with incident CAD alone were diagnosed primarily in the hospital setting (81%).
Use of Cardioprotective Medications After Incident Diagnosis
The use of cardioprotective medications within 18 months of incident diagnosis of PAD or CAD is shown in Figure 2 and online-only Data Supplement Table III . Within 3 months of incident PAD diagnosis, patients in the PAD with CAD group and the CAD alone group had greater rates of any antiplatelet use (65% and 70%, respectively), than patients with PAD alone (44%, P for difference Ͻ0.0001) (online-only Data Supplement Table III and Figure 2A ). In comparison with 3 months after incident diagnosis, by 18 months the use of any antiplatelet increased slightly in the PAD with CAD group (from 65% to 68%) and the PAD alone group (from 44% to 49%), although it decreased in the CAD alone group (from 70% to 65%). The use of statins within 3 months of incident diagnosis was also greater in the PAD with CAD group (48%) and CAD alone (51%) than the PAD alone group (33%, P for difference between groups Ͻ0.0001). There was a modest increase in the use of statins by 18 months after incident diagnosis, such that 54% of the PAD with CAD group and 37% of the PAD alone group were using statins ( Figure 2B ). Meanwhile, there was a minimal increase in the use of ACE inhibitors after incident diagnosis ( Figure 2C ) in the PAD groups. The PAD alone group had the lowest use of any cardioprotective agent during the 18-month follow-up period (PϽ0.0001). Among the CAD alone patients, use of cardioprotective medications increased most during the first 3 months after diagnosis of CAD. Figure 3 shows the annual temporal trends in use of cardioprotective medications according to group. Use of any cardioprotective medication (within the first 3 months after incident diagnosis) increased in all 3 groups from 2000 to 2007 (PϽ0.0001). Of note, use of any antiplatelet therapy after incident diagnosis nearly doubled during the study period (from 29% in 2000 to 59% in 2007, PϽ0.0001) for the PAD alone group; yet, throughout the study period, use of this therapy continued to be lowest in the PAD alone group in comparison with the other groups. Similarly, there was a near 6-fold increase in the use of statins during this study period for the PAD alone group (from 9% in 2000 to 56% in 2007, PϽ0.0001), and use of this therapy was lowest in the PAD alone group in comparison with the other groups. The temporal increase in ACE inhibitors was significant (PϽ0.0001), yet its absolute increase over the study period was the smallest among all the therapies for each of the groups.
Temporal Trends in the Use of Cardioprotective Medications
Differences in use rates of cardioprotective medications between the CAD alone group and PAD alone group (⌬ between the groups) became smaller over time. For any antiplatelet, the difference between the CAD alone and PAD alone groups decreased from 28% in 2000 to 19% in 2007, and for statin therapy, the difference between the 2 groups decreased from 22% in 2000 to 9% in 2007. The difference in the use of ACE inhibitors between the CAD alone and PAD alone groups remained stable over time. Figure 4 shows the adjusted relative differences between the groups for use of cardioprotective medications at 3 months and 18 months after incident diagnosis. In comparison with the CAD alone group, patients with PAD alone were significantly less likely to use any antiplatelet, statin therapy, and ACE inhibitor at 3 months after incident diagnosis. Meanwhile, patients in the PAD with CAD group were only less likely to use any antiplatelet (adjusted OR, 0.79; 95% confidence interval [CI], 0.75-0.83) relative to the CAD alone group. Although the use of cardioprotective medica- 
Relative Differences in the Use of Cardioprotective Medications
Other Analyses
After restricting the population to patients diagnosed in the 3 most contemporary years of the study period (2005-2007), the adjusted difference in cardioprotective medication use between the PAD alone and CAD alone groups remained significant (online-only Data Supplement Figure I ). There was a slight improvement in the adjusted odds of use of any antiplatelet and ACE inhibitor at 18 months (any antiplatelet Results were unchanged after including patients taking vitamin K antagonists (data not shown). A sensitivity analysis for the subgroups of patients with known symptomatic PAD (intermittent claudication and critical limb ischemia) showed results similar to the overall PAD population analysis, with the exception that the odds of antiplatelet treatment for patients with intermittent claudication with history of CAD were similar to the odds of the CAD alone group at 3 months after diagnosis (data not shown). However, the adjusted relative differences at 18 months after incident diagnosis were similar to the overall results.
Discussion
Our study is the largest population-based study describing the longitudinal use of cardioprotective medications after incident diagnosis of PAD and the trend in the use of these agents annually over time. With the use of the Danish nationwide administrative registries, we demonstrated that the use of cardioprotective therapies has improved dramatically over time, such that, over the course of the study period, use of statin therapy increased from 9% in 2000 to 56% in 2007, and the use of any antiplatelet increased from 29% to 59% after incident diagnosis of PAD alone. However, relative to patients with CAD, the use of these medications among PAD alone patients remains underutilized overall and among a more contemporary time period (2005) (2006) (2007) , after which the guidelines were published, despite the demonstrated benefits of these therapies among those with vascular disease. 1-4,8,9,30 -32 Our results demonstrate a temporal improvement in the use of cardioprotective agents during the study period, particularly antiplatelet therapy and statin use. Of note, use of antiplatelet and statin therapy improved in the PAD population toward the end of the study period, such that the difference in the use of these medications between the PAD alone and CAD alone groups diminished (from 28% absolute difference in the use of any antiplatelet between the PAD alone and after which the 2005 PAD guidelines were published. There was a greater uptake in the use of these therapies among the PAD with CAD group as well during this time period. The increased use of these medications over time likely reflects increased data and awareness of the vulnerability of patients with PAD. In addition, the increased use of these medications in the CAD alone group may suggest that clinicians are increasingly adhering to guideline recommendations in all groups.
Underuse of Cardioprotective Medications
Despite temporal improvements overall, the use of cardioprotective agents was modest even by the end of the study period. On average, during our study period, approximately half of the overall PAD patients used any antiplatelet medication, 40% used a statin, and 20% used an ACE inhibitor by 18 months. The use of these therapies was lowest among the PAD alone group, and this held true even after adjustment for demographics, multiple comorbidities, procedures, and temporal trends. A sensitivity analysis among those patients from 2005 to 2007, after which the guidelines were published, 5 demonstrated that, although the adjusted odds of use of these medications by the PAD alone and CAD alone groups improved in comparison with the overall study period, the PAD alone group was nearly 35% less likely to use any antiplatelet and 20% less likely to use a statin in comparison with the CAD alone group after adjustment. Such findings may reflect physicians being less aggressive in using secondary prevention treatments in PAD patients in comparison with CAD patients, although the temporal improvement hints at increasing awareness and treatment of PAD. [33] [34] [35] Throughout the study period, patients with incident diagnosis of PAD and history of CAD used cardioprotective medications more often than PAD patients without a history of CAD. However, their odds of using any antiplatelet were Ϸ25% lower than the CAD alone group within 3 months after diagnosis. The greater use of any antiplatelet immediately after incident diagnosis of CAD likely represents the greater immediate attention clinicians have placed on secondary prevention after incident diagnosis of CAD, which tended to be an in-hospital diagnosis. However, by 18 months, patients with PAD and a history of CAD were more likely than patients in the CAD alone group to use statins or ACE inhibitors and demonstrated a trend toward greater antiplatelet use (although among the more contemporary 2005-2007 population, antiplatelet use was greater in the PAD with CAD group in comparison with the CAD alone group [online-only Data Supplement Figure I] ). This change may represent greater clinician awareness of the likely greater systemic atherosclerosis in this group and resultant increased morbidity and mortality associated with polyvascular disease over long-term follow-up. 18, 31, 36 Yet, these are relative differences between groups, and, overall, the use of cardioprotective medications increased only modestly from baseline to 18 months after incident diagnosis in the PAD with CAD group (from 60% to 68% for any antiplatelet, from 41% to 54% for statins, and from 34% to 35% for ACE inhibitors). Similarly, these medications were underutilized in the CAD alone group. Consequently, there are opportunities for improvement in system approaches to increase the use of these medications in all patients with cardiovascular disease.
The suboptimal use of cardioprotective medications in the CAD alone group in this contemporary nationwide registry analysis is consistent with findings from high-income countries described in the Prospective Urban Rural Epidemiology (PURE) study by Yusuf et al. 17 In the present study, the use of antiplatelets among patients with CAD alone in 2007 was higher than the rates among patients with coronary heart disease from high-income countries in the PURE study (78% versus 64%), and statin use was slightly lower (66% versus 71%). The present study also contributes to the PURE study in that we further describe the use of cardioprotective agents in another high-risk group and different vascular bed: patients with PAD. We found that even in a high-income country like Denmark, although there were temporal improvements, the use of cardioprotective agents is suboptimal among patients with PAD and substantially lower than among those with CAD. Importantly, in comparison with stroke patients in the high-income countries in the PURE study, we observed lower rates of cardioprotective medication use by 18 months after diagnosis of PAD in the PAD alone group (antiplatelet, 53% versus 49%; statin, 52% versus 37%). This suggests that, of all the vascular beds (coronary, carotid, and lower-extremity PAD), patients with PAD and no history of CAD are treated with cardioprotective agents least aggressively.
Unlike previous cross-sectional studies using the Reduction of Atherothrombosis for Continued Health (REACH) registry and the National Health and Nutrition Examination Survey (NHANES), we were able to identify the time of incident diagnosis of PAD and subsequently describe longitudinal practice patterns for the use of cardioprotective medications after incident diagnosis. 31, 36, 37 Consequently, our analysis is unique in that our results highlight the missed opportunities for initiation of cardioprotective medications in the 18 months after incident diagnosis among a national sample of patients with PAD. Previous analyses of the REACH registry demonstrated higher cardioprotective medication use rates among all PAD patients than the present study: the REACH registry demonstrated that 80% to 83% of PAD patients used any antiplatelet, 58% to 70% used a statin, and 44% used ACE inhibitors. Among those in the REACH registry with PAD alone, the use of any antiplatelet, statin, and ACE inhibitor was higher (64%, 67%, and 42%, respectively) than the PAD alone patients in the present study, despite an earlier enrollment period within the REACH registry (December 2003 through June 2004). The greater use of these medications in the REACH registry likely reflects that it probably enrolled from a selected group of practices interested in quality improvement and research. In addition, other studies were limited because of the lack of prescription data and because they captured medication use via questionnaires. 31,36 -38 Meanwhile, our analysis may be more indicative of broad, real-world practice patterns.
Both observational and trial data support the use of cardioprotective medications to reduce ischemic events in patients with PAD. 8,9,30 -32,39,40 Consequently, the present findings underscore the continued need for systemwide improvements in identifying this high-risk PAD population in the outpatient setting and implementing quality improvement initiatives to ensure that these patients receive aggressive secondary prevention to minimize cardiovascular events. It is encouraging to see from the REACH registry and from the temporal improvement in adherence in the present study, as well, that a higher use rate of cardioprotective medications is achievable; this highlights that it is possible to improve systemwide use of these medications.
Limitations
This analysis used administrative data and, therefore, captured only those patients who were diagnosed with PAD by their clinicians. A previous study using similar ICD-10 codes for definition of PAD showed good specificity for these ICD-10 codes in the Danish population. 41 However, it is likely that we captured primarily symptomatic patients rather than asymptomatic patients, because the registry includes patients diagnosed at inpatient or outpatient specialty clinics. This is supported by the fact that the prevalence rate of PAD in patients aged Ն40 years in the present study (1.8%) is less than that of NHANES (4.3%), which defined any person with an ankle-brachial index Ͻ0.90 as having PAD (including asymptomatic patients). 42 Furthermore, nearly half of patients were diagnosed with PAD in the hospital, likely representing symptomatic patients. The higher mortality rates seen in Figure 1 are similarly likely reflective of more-symptomatic patients who probably have a greater atherosclerotic burden. Among the ICD-10 codes used, 8794 of the patients had a specific ICD-10 code for diagnosis of intermittent claudication, and 3459 had critical limb ischemia with either a specific diagnosis of atherosclerotic gangrene or rest pain (we could not differentiate symptomatic status from the rest of the codes). However, we could not determine the extent and severity of PAD and CAD with noninvasive or invasive studies given the administrative registry study design. A sensitivity analysis of the intermittent claudication and critical limb ischemia subgroups showed similar long-term results. Similarly, we could not determine actual blood pressure recordings or lipid levels given the administrative dataset. The relative differences in the use of secondary preventive medications between asymptomatic PAD patients and CAD patients would be expected to be greater than that between symptomatic PAD patients and CAD patients, although this needs to be further investigated. It remains remarkable that, even among a population with primarily symptomatic PAD, the use of cardioprotective medications remains modest even in the contemporary period.
Our findings represent all patients in Denmark, but the findings may be different in other parts of the world. Also, our analysis excluded patients with carotid, aneurysmal, renal, and mesenteric artery disease; therefore, our findings pertain to the lower-extremity atherosclerotic PAD population. Although aspirin is obtainable over-the-counter in Denmark, patients have a financial incentive to purchase prescription aspirin because they will be reimbursed. 23, 43 Furthermore, previous studies have shown that only 1.5% of aspirin prescriptions used for patients with heart disease are purchased over-the-counter without a prescription. 43 In addition, we were able to determine adherence to these medications via filled prescriptions but do not know the rates with which prescriptions were written. We assumed that at least 1 filled prescription per 3 months represented continuous treatment during that period. Certainly, it is crucial for clinicians to educate patients on the clinical significance of these preventive medications to improve adherence.
Conclusions
In this nationwide study in Denmark, we demonstrated that, despite an increased use of cardioprotective medications after incident diagnosis of PAD from 2000 to 2007, the use of these preventive medications remains modest. Throughout 18 months of follow-up, patients with PAD alone were markedly less likely to receive secondary preventive medications relative to patients with CAD, even in a more contemporary period of 2005 to 2007. Further studies are needed to improve processes of care, optimize secondary prevention strategies, improve patient education on the importance of medication compliance, and subsequently reduce cardiovascular events in this high-risk population.
